China Health Care Reform Plan To Favor Government-Made Drugs
This article was originally published in PharmAsia News
China's new three-year health care reform guidelines include a system designed to force down the cost of prescription drugs deemed essential. The government itself is to produce and distribute essential medicines under its own control and supervision. It plans to issue a list of such drugs later this year. The number of drugs to be placed on the list has not been disclosed, but the Ministry of Health had said earlier it would be based on the 400 drugs the World Health Organization recommends be accessible. Those considered essential are based on the prevalence of a disease and the comparative cost-effectiveness of the drugs. (Click here for more)
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.